Recombinant poxviruses with foreign polynucleotides in essential regions
CA 2188447 C · Owner: Immuno Aktiengesellschaft · Inventors: Dorner, Friedrich; Falkner, Falko-Gunter; Holzer, Georg
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus can be employed for protein production and vaccination, among other uses. A polynucleotide encoding the protein to be produced by the recombinant virus is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell transgenic animal or helper virus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 28, 1995 and granted October 22, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 28, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 28, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.